Phillip D. Zamore is an American molecular biologist and biochemist who co-developed the first in vitro system for studying the mechanism of RNA interference (RNAi).

[3] In addition to a focus on basic research, the Zamore lab is working to develop novel nucleic acid-based drugs to treat human disease.

[1] After completing postdoctoral studies at The Whitehead Institute for Biomedical Research, MIT, and the Skirball Institute at New York University Medical Center with Ruth Lehmann, James R. Williamson, and David Bartel, Zamore began his academic career as an assistant professor in the Department of Biochemistry and Molecular Pharmacology in 1999 at UMass Medical School in Worcester, Massachusetts.

Zamore's research has led to a career in biotechnology, co-founding Alnylam Pharmaceuticals in 2002.

[5] Alnylam is dedicated to bringing RNAi based therapies to market and developed the first-ever FDA approved RNAi drug, Patisiran, gaining FDA approval in August 2018.